Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alphamab Oncology ( (HK:9966) ) has provided an announcement.
Alphamab Oncology announced that its drug JSKN003 has received approval from the U.S. FDA to begin a phase II clinical study for treating platinum-resistant ovarian cancer not restricted by HER2 expression. This approval is a significant milestone in Alphamab’s global development strategy, enhancing its competitive position in oncology therapeutics. The study will assess the safety and efficacy of JSKN003, a biparatopic HER2-targeting antibody-drug conjugate, and determine the recommended phase III dose. This development is expected to strengthen Alphamab’s innovative pipeline and impact its stakeholders positively.
More about Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company in China, specializing in antibody-drug conjugates (ADCs), bispecific antibodies, and multi-functional protein engineering. The company has developed a proprietary technology platform and a highly differentiated pipeline of oncology therapeutics, including ADCs, monoclonal antibodies, and bispecific antibodies, with one product approved for marketing in China and several others in advanced clinical trial stages.
Average Trading Volume: 4,214,814
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.98B
Learn more about 9966 stock on TipRanks’ Stock Analysis page.